drug · small molecule
vadadustat
Marketedupdated 3mo agoby $AKBA Akebia Therapeutics, Inc.🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 1 investigational indication.
targets
Egl nine homolog 1Prolyl hydroxylase EGLN2Prolyl hydroxylase EGLN3
all catalysts(2)
Trials studying vadadustat
- phase3Vafseo Outcomes In-Center Experience
- phase3To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis
- phase3Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agents
- phase3Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease
- phase3Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)
- phase3Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jun 26, 2027
312 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (42)
- Mar 31, 2036formulationUS 11324734
- Mar 31, 2036formulationUS 11324734
- Mar 31, 2036formulationUS 11324734
- Mar 31, 2036method-of-use (U-3876)US 11844756
- Mar 31, 2036method-of-use (U-3876)US 11844756
- Mar 31, 2036method-of-use (U-3876)US 11844756
- Nov 14, 2034compositionUS 10149842
- Nov 14, 2034compositionUS 10149842
- Nov 14, 2034compositionUS 10149842
- Nov 14, 2034compositionUS 11065237
- Nov 14, 2034compositionUS 11065237
- Nov 14, 2034compositionUS 11065237
- Nov 14, 2034compositionUS 9701636
- Nov 14, 2034compositionUS 9701636
- Nov 14, 2034compositionUS 9701636
- Nov 14, 2034method-of-use (U-3876)US 9987262
- Nov 14, 2034method-of-use (U-3876)US 9987262
- Nov 14, 2034method-of-use (U-3876)US 9987262
- Jun 9, 2034method-of-use (U-3876)US 11857543
- Jun 9, 2034method-of-use (U-3876)US 11857543
- Jun 9, 2034method-of-use (U-3876)US 11857543
- Jun 4, 2034method-of-use (U-3876)US 12569474
- Jun 4, 2034method-of-use (U-3876)US 12569474
- Jun 4, 2034method-of-use (U-3876)US 12569474
- Apr 3, 2028method-of-use (U-3876)US 83236711.6y
- Apr 3, 2028method-of-use (U-3876)US 83236711.6y
- Apr 3, 2028method-of-use (U-3876)US 83236711.6y
- Mar 13, 2028compositionUS 78115951.6y
- Mar 13, 2028compositionUS 78115951.6y
- Mar 13, 2028compositionUS 78115951.6y
- Aug 14, 2027compositionUS 8343952361d
- Aug 14, 2027compositionUS 8343952361d
- Aug 14, 2027compositionUS 8343952361d
- Jun 26, 2027compositionUS 8598210312d
- Jun 26, 2027compositionUS 8598210312d
- Jun 26, 2027compositionUS 8598210312d
- Jun 26, 2027method-of-use (U-3876)US 8940773312d
- Jun 26, 2027method-of-use (U-3876)US 8940773312d
- Jun 26, 2027method-of-use (U-3876)US 8940773312d
- Jun 26, 2027compositionUS RE47437312d
- Jun 26, 2027compositionUS RE47437312d
- Jun 26, 2027compositionUS RE47437312d
FDA exclusivities (3)
- Mar 27, 2029NCENew Chemical Entity (5y)2.6y
- Mar 27, 2029NCENew Chemical Entity (5y)2.6y
- Mar 27, 2029NCENew Chemical Entity (5y)2.6y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 25m ago
Found something off?
comments(0)
5-min edit window · permanent after that